SCHEMBL483070

SCHEMBL483070

CC(C)(C)Oc1ncc(-c2cc(-c3ccc4cc(NS(C)(=O)=O)ccc4c3)c(N)c(C(C)(C)C)c2)c(OC(C)(C)C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.45
ATM Q13315 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
CRBN Q96SW2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.38
ACVR1 Q04771 2/20 0.34
FYN P06241 1/20 0.34
TGFBR1 P36897 1/20 0.34
PTK2 Q05397 1/20 0.33
NR3C1 P04150 1/20 0.33
AR P10275 1/20 0.33
IKBKB O14920 4/20 0.33
CHUK O15111 4/20 0.33
ABL1 P00519 2/20 0.33
DHFR P00374 1/20 0.33
RIPK2 O43353 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL896915 0.89 NPSR1 (0.45) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL897090 0.89 NPSR1 (0.45) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL482910 0.89 CRBN (0.53) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL896547 0.88 NPSR1 (0.44) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL897030 0.85 NPSR1 (0.48) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL897068 0.83 CRBN (0.49) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL896311 0.83 CRBN (0.46) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL896347 0.82 NPSR1 (0.48) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL482581 0.80 NPSR1 (0.46) NPSR1ATMMEN1KMT2AKDM4E
SCHEMBL896604 0.80 NPSR1 (0.46) NPSR1ATMMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9637478-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2017-05-02 US disclosed
EP-2411352-B1 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBVIE INC (US) 2017-01-18 EP disclosed
US-20160368905-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBOTT LABORATORIES 2016-12-22 US disclosed
US-9353091-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2016-05-31 US disclosed
US-20150056164-A1 Antiviral Compounds and Uses Thereof ABBVIE INC. (US) 2015-02-26 US disclosed
US-8748443-B2 Antiviral compounds and uses thereof ABBVIE INC. (US) 2014-06-10 US disclosed
US-20120082646-A1 Antiviral Compounds And Uses Thereof ABBOTT LABORATORIES (US) 2012-04-05 US disclosed
EP-2411352-A2 ANTIVIRAL COMPOUNDS AND USES THEREOF Abbott Laboratories (US) 2012-02-01 EP disclosed
WO-2010111436-A2 ANTIVIRAL COMPOUNDS AND USES THEREOF ABBOTT LABORATORIES (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150056164-A1 Antiviral Compounds and Uses Thereof MAVS, ZC3HAV1, EIF2AK2 NPSR1 4135/4885ATM 4521/4885MEN1 3996/4885
US-20160368905-A1 ANTIVIRAL COMPOUNDS AND USES THEREOF MAVS, ZC3HAV1, EIF2AK2 NPSR1 4135/4885ATM 4521/4885MEN1 3996/4885
US-20120082646-A1 Antiviral Compounds And Uses Thereof MAVS, ZC3HAV1, EIF2AK2 NPSR1 4135/4885ATM 4521/4885MEN1 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.